Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Amicus Therapeutics (FOLD) Other Gross PP&E Adjustments (2016 - 2025)

Amicus Therapeutics filings provide 15 years of Other Gross PP&E Adjustments readings, the most recent being $37.8 million for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 5.33% to $37.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.8 million, a 5.33% increase, with the full-year FY2025 number at $37.8 million, up 5.33% from a year prior.
  • Other Gross PP&E Adjustments hit $37.8 million in Q4 2025 for Amicus Therapeutics, up from -$21.5 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $41.8 million in Q4 2021 to a low of -$32.0 million in Q3 2023.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$22.3 million (2021), compared with a mean of -$10.6 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: skyrocketed 31.19% in 2021 and later plummeted 43.71% in 2022.
  • Amicus Therapeutics' Other Gross PP&E Adjustments stood at $41.8 million in 2021, then tumbled by 43.71% to $23.5 million in 2022, then surged by 30.86% to $30.8 million in 2023, then grew by 16.55% to $35.9 million in 2024, then rose by 5.33% to $37.8 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $37.8 million (Q4 2025), -$21.5 million (Q3 2025), and -$22.0 million (Q2 2025) per Business Quant data.